<?xml version="1.0" encoding="UTF-8"?>
<p>Serum samples were screened for exposure to dengue and Zika infection using the PanBio
 <sup>®</sup> Dengue NS1 ELISA (Abbott, Santa Clara, CA, USA; former Alere Inc., Waltham, MA, USA)
 <bold>,</bold> human anti-DENV IgM ELISA (Abcam, Cambridge, UK) and the EUROIMMUN human IgM anti-ZIKV ELISA (EUROIMMUN, EURO-AG, Luebeck, Germany). CSF samples were screened using the NovaTech human anti-DENV IgM and anti-ZIKV IgM ELISA kits (NovaTech Immundiagnostica GmbH, Dietzenbach, Germany). All assays were performed according to the manufacturer’s recommendations using the corresponding positive and negative controls for quality control. ELISA plates were read using a Spectramax Plus ELISA reader at 450 nm (Molecular Devices, LLC, San Jose, CA, USA). Results were expressed in Standard Units (PU) and interpreted as &lt;0.8 negative, &gt;0.8 and &lt;1.1 equivocal and &gt;1.1 positive.
</p>
